CDK4 and neoplasm: Notably, clinical history for patient HT77 indicated that the CDK4/6 inhibitor palbociclib was given to the patient, albeit at a much later phase in the disease’s journey of progression (Figure 16A), such that the therapy may not have been able to compete against the increased tumor burden.